Live coverage has ended. The full story is below.
UnitedHealth Group (NYSE: UNH | UNH Price Prediction) posted mixed second-quarter results, as topline revenue of $111.6B beat expectations, but adjusted EPS of $4.08 sharply missed analyst estimates of $5.99. The company’s performance was dragged down by a $1.2B charge tied to its individual exchange business and other discrete items. Despite the earnings miss, UNH reinstated full-year guidance and struck a constructive tone on its long-term recovery path.
So far in pre-market trading, the stock is down 2.18% as of 8:30 AM EDT.
| Metric |
Estimate |
Actual |
Result |
| Revenue |
$111.59B |
$111.62B |
✅ Beat |
| Adj. EPS |
$5.99 |
$4.08 |
❌ Miss |
| Net Margin |
– |
3.1% |
❌ Miss YoY (4.3%) |
| Medical Cost Ratio |
– |
89.4% |
❌ Unfavorable YoY (+430 bps) |
Guidance Update: UNH Reinstates Full-Year Outlook
After suspending its 2025 forecast in May due to volatility in medical trends, UNH has reinstated its full-year guidance:
-
FY25 Adjusted EPS: At least $16.00
-
FY25 Revenue: $445.5B–$448.0B
-
Medical Cost Ratio: 89.25% ± 25 bps
-
Operating Margin: 4.8%–5.0%
This implies a more stable second half, even though pricing still lags the cost trend in key segments.
We’ve embarked on a rigorous path back to being a high-performing company fully serving the health needs of individuals and society… guided by a culture of service and longstanding values
CEO Stephen Hemsley emphasized a shift toward cost discipline and long-term structural improvements:
Contact [email protected] for any questions or corrections.